Opportunities and challenges of implementing Pharmacogenomics in cancer drug development

Cancer drug development is a time and resources consuming process. Around 90% of drugs entering clinical trials fail due to lack of efficacy and/or safety issues, more often after conspicuous research and economic efforts. Part of the discarded drugs might be beneficial only in a subgroup of the stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantino, Paolo, Trapani, Dario, Morganti, Stefania, Ferraro, Emanuela, Viale, Giulia, D’Amico, Paolo, Duso, Bruno Achutti, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019172/
https://www.ncbi.nlm.nih.gov/pubmed/35582141
http://dx.doi.org/10.20517/cdr.2018.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019172/
https://www.ncbi.nlm.nih.gov/pubmed/35582141
http://dx.doi.org/10.20517/cdr.2018.22

Ejemplares similares